Coherus BioSciences Renames to Coherus Oncology, Focusing on Cancer Treatments.

Coherus BioSciences has rebranded as Coherus Oncology, focusing exclusively on innovative cancer treatments. The company's pipeline includes FDA-approved LOQTORZI and other promising candidates targeting various cancers. Coherus Oncology is backed by a prestigious team from leading institutions and companies like Merck and the Cancer Research Institute. The rebranding aligns with its strategic focus on developing proprietary cancer therapeutics with higher potential margins and market opportunities.